1795-Prophylaxis - antiviral therapy for herpes simplex virus (HSV) and varicella zoster virus (VZV)

This document is an evidence-based summary to complement treatment protocols and includes background and rationale for specific point of care actions. It is not intended to be a comprehensive literature review of all available evidence.

Background

Morbidity and mortality in patients with malignancies are increased by viral infections. This document is intended to provide guidance for both primary and secondary prophylaxis of viral infections among adult patients with haematological malignancies, solid tumours or undergoing blood and marrow transplant (BMT). However, it is anticipated that individual units or practitioners will adopt local antiviral strategies.

Pathophysiology

Most viral infections in patients with haematological malignancies, solid tumours or undergoing BMT result from reactivation of asymptomatic latent infections, predominantly of herpes viruses, such as herpes simplex virus (HSV) and varicella zoster virus (VZV).

Risk factors

The risk of viral reactivation is determined by baseline serostatus. HSV reactivation commonly occurs in the setting of mucositis and neutropenia, whereas VZV is common in therapies that are T-cell depleting. Patients at highest risk of reactivation of both HSV and VZV are allogeneic stem cell transplant recipients, in particular those who have received T-cell depleting conditioning regimens and who remain on long term immunosuppression for graft versus host disease. For those allogeneic transplant recipients, the pre-engraftment period during which mucositis occurs is the time of heightened risk of HSV. HSV prophylaxis may be extended beyond this time in patients who experience frequent HSV recurrences.^r

Herpes simplex virus (HSV)

Herpes simplex virus is an important pathogen in patients who develop neutropenia and mucositis. HSV infections are primarily reactivation of the latent virus. The presence of latent HSV can be determined by pre-treatment HSV serology. Reactivation and infections with HSV occur in 60 to 80% of BMT recipients and in acute leukaemia patients with no primary HSV prophylaxis undergoing induction or re-induction therapy. Once a patient has had HSV reactivation requiring treatment, it is recommended that HSV prophylaxis is administered during all future anti-cancer treatment and during any episodes of treatment-induced neutropenia.^r

Varicella zoster virus (VZV)

The principal risk factor for VZV is impaired cellular immunity. In allogeneic BMT recipients with a history of VZV infection, about 30% without antiviral prophylaxis experience VZV reactivation. If appropriate, consider VZV immunisation (see the Australian Immunisation Handbook opens in a new tab or window for more information). Patients who are VZV seropositive pre transplant should receive prophylaxis for at least 12 months post allogeneic transplant. This has been shown to significantly decrease the incidence of VZV disease compared to placebo (5% vs. 26% respectively).^r Continuation of prophylaxis beyond this time is recommended in patients with chronic graft-versus-host disease (cGVHD) who continue on immunosuppression. Prophylaxis may be discontinued when CD4 counts are greater than 200 cells/microlitres and immunosuppressive therapy is ceased.

Assessment and management

Grading

Risk categories^r ^r are based on several factors, including:

Table 1. Antiviral prophylaxis recommendations

The information below is based on local and international guidelines as well as clinical expertise from eviQ Haematology and BMT reference committees.^r ^r
Antiviral drug doses should be adjusted in patients with kidney dysfunction.

Risk category	Disease/therapy	Duration	Antiviral dose (oral) *
High risk	Acute lymphoblastic leukaemia	HSV prophylaxis: during active therapy including periods of neutropenia and/or mucositis	Valaciclovir HSV or VZV: 500 mg orally TWICE daily OR Aciclovir HSV or VZV: 800 mg orally TWICE daily
	Acute myeloid leukaemia, or myelodysplastic syndrome high intensity regimens	HSV and/or VZV prophylaxis: during active therapy including periods of neutropenia and/or mucositis
	Allogeneic BMT	HSV prophylaxis: during active therapy including periods of neutropenia and/or mucositis for at least 30 days after BMT VZV prophylaxis: consider for at least 1 year after BMT Continue HSV and VZV prophylaxis for longer if there is ongoing immunosuppression.
	Graft versus host disease (GVHD) requiring steroid treatment	HSV and/or VZV prophylaxis: during periods of neutropenia and ongoing immunosuppression
	Alemtuzumab	HSV and/or VZV prophylaxis: for a minimum of 2 months after treatment and until CD4 count is greater than 200 cells/microL
	Proteasome inhibitors (e.g. bortezomib, carfilzomib) - see notes below	HSV and VZV prophylaxis: during active therapy including periods of neutropenia
Intermediate	Autologous BMT	HSV prophylaxis: during active therapy and at least 30 days after transplant VZV prophylaxis: consider for at least 6 to 12 months post transplant	Valaciclovir HSV: 500 mg orally daily VZV: 500 mg orally TWICE daily OR Aciclovir HSV: 400 mg to 800 mg orally TWICE daily VZV: 800 mg orally TWICE daily
	Lymphoma	HSV and/or VZV prophylaxis: consider depending on regimen intensity. Use if prior HSV episode during chemotherapy.
	Chronic lymphocytic leukaemia
	Multiple myeloma (non-proteasome inhibitor regimens)
	Purine analogue therapy (e.g. cladribine, fludarabine)	HSV and/or VZV prophylaxis: throughout treatment and for 1 month after stopping treatment
	Methotrexate dose ≥1 g/m²
Low	Standard chemotherapy regimens for solid tumours	HSV prophylaxis: none unless prior HSV episode during chemotherapy. If required, continue prophylaxis during active therapy including periods of neutropenia.	Prophylaxis is NOT generally required in patients receiving conventional doses of chemotherapy as they do not experience significant T-cell depletion. Valaciclovir 500 mg orally daily OR Aciclovir 400 mg orally TWICE daily

* For patients who are unable to tolerate oral therapy, use aciclovir IV 5 mg/kg every 8 hours^r

Notes:

For patients who are receiving antiviral prophylaxis for prevention of cytomegalovirus (CMV) reactivation, additional prophylaxis for HSV and VZV is not necessary.^r
Once a patient has had HSV reactivation requiring treatment, HSV prophylaxis is recommended during all future active anticancer treatment and episodes of neutropenia induced by treatment.^r
Low dose antiviral prophylaxis (e.g. valaciclovir 500mg orally daily or aciclovir 400mg orally twice daily) has been demonstrated to be effective in preventing VZV in patients with multiple myeloma receiving bortezomib treatment. Choice of antiviral dosing may be based upon individual patient risk factors, clinician discretion and local institutional policies.^r ^r
Consider low dose antiviral prophylaxis ('suppressive therapy') for patients with recurrent oral mucocutaneous or genital HSV infection.^r

References References

[%id%]: [%title%]

Read abstract

[%abstract%]
: Chanan-Khan, A., P. Sonneveld, M. W. Schuster, et al. 2008. "Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study." J Clin Oncol. 26(29):4784-4790

Read abstract

PURPOSE: The aim of this subset analysis was to determine if bortezomib treatment is associated with increased incidence of varicella-zoster virus (VZV) reactivation in patients with relapsed multiple myeloma (MM). PATIENTS AND METHODS: Incidence of herpes zoster was evaluated in 663 patients with relapsed MM from the phase III APEX trial comparing single-agent bortezomib with high-dose dexamethasone. RESULTS: Bortezomib was associated with a significantly higher incidence of herpes zoster compared with dexamethasone treatment (13%, 42 of 331 v 5%, 15 of 332; P = .0002). Most herpes zoster infections were grade 1/2; incidences of grade 3/4 events (1.8% v 1.5%) and infections considered serious adverse events (1.5% v 0.9%) were similar between treatment arms, and no herpes zoster-related deaths occurred. Neither the time to onset of the herpes event nor the patients' absolute lymphocyte counts at baseline differed significantly between arms. VZV reactivation was the only herpes viral event noted to be significantly elevated in the bortezomib treatment group compared with the dexamethasone treatment group (P = .0002). The incidence of non-VZV-related herpes viral infections was comparable between arms. No additional risk factors for herpes zoster reactivation were identified. CONCLUSION: Further studies are needed to explain these observations and their implications; however, for patients treated with bortezomib or bortezomib-containing regimens, the risk of VZV reactivation should be monitored and routine use of antiviral prophylaxis considered
: Erard V, Guthrie KA, Varley C et al. 2007 . " One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood. Oct 15;110(8):3071-7

Read abstract

No consensus exists on whether acyclovir prophylaxis should be given for varicella-zoster virus (VZV) prophylaxis after hematopoietic cell transplantation because of the concern of rebound VZV disease after discontinuation of prophylaxis. To determine whether rebound VZV disease is an important clinical problem and whether prolonging prophylaxis beyond 1 year is beneficial, we examined 3 sequential cohorts receiving acyclovir from day of transplantation until engraftment for prevention of herpes simplex virus reactivation (n = 932); acyclovir or valacyclovir 1 year (n = 1117); or acyclovir/valacyclovir for at least 1 year or longer if patients remained on immunosuppressive drugs (n = 586). In multivariable statistical models, prophylaxis given for 1 year significantly reduced VZV disease (P < .001) without evidence of rebound VZV disease. Continuation of prophylaxis beyond 1 year in allogeneic recipients who remained on immunosuppressive drugs led to a further reduction in VZV disease (P = .01) but VZV disease developed in 6.1% during the second year while receiving this strategy. In conclusion, acyclovir/valacyclovir prophylaxis given for 1 year led to a persistent benefit after drug discontinuation and no evidence of a rebound effect. To effectively prevent VZV disease in long-term hematopoietic cell transplantation survivors, additional approaches such as vaccination will probably be required.
: Liesveld JL, Abboud CN, Ifthikharuddin JJ et al. 2002 . " Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients". Biol Blood Marrow Transplant. ;8(12):662-5.

Read abstract

Patients who are seropositive for herpes simplex virus (HSV) and are undergoing autologous marrow or peripheral blood stem cell transplantation require prophylaxis for HSV infection. Most prophylaxis regimens have used intravenous acyclovir (ACY). Oral valacyclovir (VAL), the L-valyl ester of ACY, can be used to achieve plasma concentrations equivalent to levels achieved with intravenous ACY. In this study, adults undergoing autologous stem cell transplantation were randomized to receive ACY, 250 mg/m2 intravenously (IV) every 12 hours from day 0 to engraftment, or VAL, 1 g orally every 12 hours from day 0 to engraftment. The primary study objective was to compare cost of HSV prophylaxis between study groups. Thirty patients were randomized to receive either oral VAL (n = 14) or IV ACY (n = 16) prophylaxis. Mean pharmacy cost of HSV prophylaxis in the patient group randomized to IV ACY was $1080 versus $320 for the group randomized initially to VAL. This study demonstrates the feasibility and significant cost savings of using oral VAL for HSV prophylaxis.
: Minarik, J., T. Pika, J. Bacovsky et al. 2012. "Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients." Br J Haematol 159:104-119

Read abstract
: Oshima K, Takahashi T, Mori T et al. 2010 " One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group". Transpl Infect Dis. Oct;12(5):421-7.

Read abstract

Varicella zoster virus (VZV) disease is a frequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). We carried out a trial of 1-year low-dose valacyclovir (VCV) prophylaxis against VZV disease to evaluate its efficacy and safety. Patients received oral acyclovir (ACV) 1000mg/day until day 35 after HSCT. Oral VCV 500mg/day, 3 times a week, was started on day 36 and continued until 1 year after HSCT. The development of VZV disease was monitored until 2 years after HSCT. A total of 40 patients with a median age of 43 years were enrolled. VCV was well tolerated in all but 1 patient who discontinued it on day 224 because of thrombocytopenia of unknown cause. Seven patients developed VZV disease at a median of 479 days (range 145-651) after HSCT, with a cumulative incidence of 18.5%. Two patients developed breakthrough disease during VCV prophylaxis. The other 5 patients developed VZV disease after the discontinuation of VCV, and 3 of these had developed extensive chronic graft-versus-host disease. Visceral involvement and serious complications were completely eliminated. All patients responded to the therapeutic dose of VCV or ACV. One-year low-dose VCV can be safely and effectively administered for the prevention of VZV disease after allogeneic HSCT.
: Sandherr, M., M. Hentrich, M. von Lilienfeld-Toal et al. 2015. "Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)." Ann Hematol 94(9):1441-1450.

Read abstract

Reactivation of viral infections is common in patients with solid tumour or haematological malignancy. Incidence and severity depend on the extent of cellular immunosuppression. Antiviral prophylaxis may be effective to prevent viral reactivation. In 2006, the Infectious Diseases Working Party of German Society for Hematology and Medical Oncology (DGHO) published guidelines for antiviral prophylaxis in these patient populations. Here, we present an update of these guidelines for patients with solid and haematological malignancies undergoing antineoplastic treatment but not allogeneic stem cell transplantation. Relevant literature for reactivation of different viruses (herpes simplex virus (HSV), varicella zoster virus (VZV), hepatitis B virus (HBV) and respiratory viruses) is discussed to provide evidence-based recommendations for clinicians taking care of this patient population. We recommend a risk-adapted approach with (val)acyclovir against HSV and VZV in patients treated with alemtuzumab, bortezomib or purine analogues. Seasonal vaccination against influenza is recommended for all patients with solid or haematological malignancies regardless of antineoplastic therapy. Hepatitis B screening is recommended in lymphoproliferative disorders, acute leukaemia, and breast cancer, and during treatment with monoclonal anti-B-cell antibodies, anthracyclines, steroids and in autologous stem cell transplantation. In those with a history of hepatitis B prophylactic lamivudine, entecavir or nucleotide analogues as adefovir are recommended to prevent reactivation.
: Taplitz, R. A., E. B. Kennedy, E. J. Bow et al. 2018. "Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update." J Clin Oncol 36(30):3043-3054.

Read abstract

PURPOSE: To provide an updated joint ASCO/Infectious Diseases Society of America (IDSA) guideline on antimicrobial prophylaxis for adult patients with immunosuppression associated with cancer and its treatment. METHODS: ASCO and IDSA convened an update Expert Panel and conducted a systematic review of relevant studies from May 2011 to November 2016. The guideline recommendations were based on the review of evidence by the Expert Panel. RESULTS: Six new or updated meta-analyses and six new primary studies were added to the updated systematic review. RECOMMENDATIONS: Antibacterial and antifungal prophylaxis is recommended for patients who are at high risk of infection, including patients who are expected to have profound, protracted neutropenia, which is defined as < 100 neutrophils/microL for > 7 days or other risk factors. Herpes simplex virus-seropositive patients undergoing allogeneic hematopoietic stem-cell transplantation or leukemia induction therapy should receive nucleoside analog-based antiviral prophylaxis, such as acyclovir. Pneumocystis jirovecii prophylaxis is recommended for patients receiving chemotherapy regimens that are associated with a > 3.5% risk for pneumonia as a result of this organism (eg, those with >/= 20 mg prednisone equivalents daily for >/= 1 month or on the basis of purine analog usage). Treatment with a nucleoside reverse transcription inhibitor (eg, entecavir or tenofovir) is recommended for patients at high risk of hepatitis B virus reactivation. Recommendations for vaccination and avoidance of prolonged contact with environments that have high concentrations of airborne fungal spores are also provided within the updated guideline.
: Thursky, K. A., L. J. Worth, J. F. Seymour, et al. 2006. "Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*." Br J Haematol 132(1):3-12.

Read abstract

There is an increasing use of monoclonal antibodies in the treatment of haematological malignancies. Alemtuzumab (Campath-1H; Ilex Pharmaceuticals, San Antonio, TX, USA) is a monoclonal antibody reactive with the CD52 antigen used as first and second line therapy for two types of lymphoproliferative disorders: chronic lymphocytic leukaemia (CLL), and T-cell lymphomas [both peripheral (PTCL) and cutaneous (CTCL)]. With alemtuzumab therapy, viral, bacterial and fungal infectious complications are frequent, and may be life threatening. An understanding of the patients at highest risk and duration of risk are important in developing recommendations for empirical management, antimicrobial prophylaxis and targeted surveillance. This review discusses the infection risks associated with these lymphoproliferative disorders and their treatment, and provide detailed recommendations for screening and prophylaxis

Literature search

Flinders Filters has partnered with eviQ to build reliable, robust search filters to retrieve core high level evidence on topics of significance to eviQ. The project goal is the provision of a sustainable model for evidence retrieval to ensure ongoing currency of content.

These search filters have been developed to retrieve the most up to date evidence from PubMed, in real time, using specifically designed search filters built to meet our needs.

Guidelines and reviews is a search filter used when there is a low volume of high level evidence available. Please click on this link opens in a new tab or window to access the Pubmed searches.

Access Flinders Filters opens in a new tab or window, a division of the Flinders Digital Health Research Centre at Flinders University to read more about research solutions to searching problems.

Troubleshooting

Occasionally the searches may not display correctly or take too long to load (and will eventually timeout). This may be caused by Internet Explorer being unable to handle long URL's. You can rectify this by using Firefox, Safari or Google chrome. It is always a good idea to clear the cache regularly to ensure you are getting the most up to date search.

Feedback

If you identify any new articles that you believe should be included in the content, please use the feedback button below to inform us of the name of the article(s).

History

Version 6

Date	Summary of changes
10/08/2023	Link to Australian Immunisation Handbook added to background section. Aciclovir dose for low risk updated in management table and notes updated.

Version 5

Date	Summary of changes
16/12/2019	Reviewed by the Haematology Reference Committee, updated in light of Therapeutic Guideline changes. Version number changed to V.5. Review in 2 years.
22/06/2021	Note added regarding low dose prophylaxis for patients receiving bortezomib-based treatment.
30/07/2021	Electronically reviewed by eviQ BMT Reference Committee.

Version 4

Date	Summary of changes
20/05/2016	Review at haematology reference committee meeting and by external clinicians: - converted to new format - updated as per "Therapeutic Guidelines (eTG March 2016 edition)" - minor changes to wording made. ie. HPCT change to BMT
15/08/2016	Addition of sentence regarding the intent of this document.
31/05/2017	Transferred to new eviQ website. Version number changed to V.3
03/08/2018	Reviewed and updated as per Therapeutic Guidelines (eTG July 2018 edition) and NCCN Prevention and treatment of cancer-related infections v.1.2018. Version number changed to V.4

This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information source. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page

First approved:: 10 December 2009
Last reviewed:: 7 August 2023
Review due:: 30 June 2025

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/1795

12 Apr 2025

Herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis in immunocompromised adults